4.7 Article

Positive Selection of Plasmodium falciparum Parasites With Multiple var2csa-Type PfEMP1 Genes During the Course of Infection in Pregnant Women

Journal

JOURNAL OF INFECTIOUS DISEASES
Volume 203, Issue 11, Pages 1679-1685

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jir168

Keywords

-

Funding

  1. Danish National Research Foundation Niels Bohr Foundation [312000-50-64920]
  2. National Institute of Allergy and Infectious Diseases National Institutes of Health [UO1AI43888]

Ask authors/readers for more resources

Placental malaria infections are caused by Plasmodium falciparum-infected red blood cells sequestering in the placenta by binding to chondroitin sulfate A, mediated by VAR2CSA, a variant of the PfEMP1 family of adhesion antigens. Recent studies have shown that many P. falciparum genomes have multiple genes coding for different VAR2CSA proteins, and parasites with >1 var2csa gene appear to be more common in pregnant women with placental malaria than in nonpregnant individuals. We present evidence that, in pregnant women, parasites containing multiple var2csa-type genes possess a selective advantage over parasites with a single var2csa gene. Accumulation of parasites with multiple copies of the var2csa gene during the course of pregnancy was also correlated with the development of antibodies involved in blocking VAR2CSA adhesion. The data suggest that multiplicity of var2csa-type genes enables P. falciparum parasites to persist for a longer period of time during placental infections, probably because of their greater capacity for antigenic variation and evasion of variant-specific immune responses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines

Louise Goksoyr, Magdalena Skrzypczak, Maureen Sampson, Morten A. Nielsen, Ali Salanti, Thor G. Theander, Alan T. Remaley, Willem A. De Jongh, Adam F. Sander

Summary: Administration of PCSK9-specific monoclonal antibodies and peptide-based PCSK9 vaccines can reduce plasma LDL cholesterol by blocking PCSK9. However, these treatments also increase plasma PCSK9 levels due to the formation of immune complexes. A study using a cVLP-based vaccine platform shows that the FL PCSK9 cVLP vaccine has an enhanced ability to opsonize and clear plasma PCSK9. These findings have implications for the design of vaccines that can effectively mediate opsonization and immune clearance of target antigens.

VACCINES (2023)

Article Infectious Diseases

First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2

Merel J. Smit, Adam F. Sander, Maud B. P. A. Ariaans, Cyrielle Fougeroux, Constanze Heinzel, Rolf Fendel, Meral Esen, Peter G. Kremsner, Rob ter Heine, Heiman F. Wertheim, Manja Idorn, Alexander P. Underwood, Alekxander Binderup, Santseharay Ramirez, Jens Bukh, Max Soegaard, Sayit M. Erdogan, Tobias Gustavsson, Stine Clemmensen, Thor G. Theander, Lancet Microbe, Ali Salanti, Mette Hamborg, Willem A. de Jongh, Matthew B. B. McCall, Morten A. Nielsen, Benjamin G. Mordmuller

Summary: A clinical trial was conducted in the Netherlands to test a cVLP-based COVID-19 vaccine. The results showed that the vaccine exhibited high immunogenicity at antigen levels of 25-70 mu g and had high virus neutralization activity against major SARS-CoV-2 variants.

LANCET MICROBE (2023)

Article Oncology

Bispecific T cell-engager targeting oncofetal chondroitin sulfate induces complete tumor regression and protective immune memory in mice

Nanna Skeltved, Mie A. A. Nordmaj, Nicolai T. T. Berendtsen, Robert Dagil, Emilie M. R. Stormer, Nader Al-Nakouzi, Ke Jiang, Alexandra Aicher, Christopher Heeschen, Tobias Gustavsson, Swati Choudhary, Ismail Gogenur, Jan P. P. Christensen, Thor G. G. Theander, Mads Daugaard, Ali Salanti, Morten A. A. Nielsen

Summary: The malaria protein VAR2CSA has anti-tumor efficacy by binding to oncofetal chondroitin sulfate (ofCS). Combining V-aCD3 with an immune checkpoint inhibitor enhances the anti-tumor effects, leading to complete elimination of solid tumors in mice.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Article Immunology

High immunogenicity of virus-like particles (VLPs) decorated with Aeromonas salmonicida VapA antigen in rainbow trout

Jeong In Yang, Dagoberto Sepulveda, Irina Vardia, Jakob Skov, Louise Goksoyr, Adam F. F. Sander, Niels Lorenzen

Summary: This study aimed to develop and test a recombinant alternative vaccine based on virus-like particles (VLPs) decorated with VapA protein as the key structural surface protein for combating A. salmonicida bacterial disease. The results showed that rainbow trout vaccinated with VapA-VLP vaccines exhibited comparable protection to the bacterin-based vaccine and produced a strong VapA-specific antibody response.

FRONTIERS IN IMMUNOLOGY (2023)

Article Immunology

Characterization of SARS-CoV-2 humoral immune response in a subject with unique sampling: A case report

Melanie R. Walker, Manja Idorn, Anja Bennett, Max Sogaard, Ali Salanti, Sisse B. Ditlev, Lea Barfod

Summary: The study found that new variants of the SARS-CoV-2 virus are less susceptible to vaccine-induced immunity, leading to breakthrough infections among vaccinated individuals. The research also revealed the significant role of different types and subclasses of immunoglobulins in the immune response during vaccination and breakthrough infections.

IMMUNITY INFLAMMATION AND DISEASE (2023)

Article Veterinary Sciences

Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA

Justin Doritchamou, Morten A. Nielsen, Arnaud Chene, Nicola K. Viebig, Lynn E. Lambert, Adam F. Sander, Jean-Philippe Semblat, Sophia Hundt, Sachy Orr-Gonzalez, Christoph Mikkel Janitzek, Alicia J. Spiegel, Stine B. Clemmensen, Marvin L. Thomas, Martha C. Nason, Maryonne Snow-Smith, Emma K. Barnafo, Joseph Shiloach, Beth B. Chen, Steven Nadakal, Kendrick Highsmith, Tarik Ouahes, Solomon Conteh, Ankur Sharma, Holly Torano, Brandi Butler, Karine Reiter, Kelly M. Rausch, Puthupparampil V. Scaria, Charles Anderson, David L. Narum, Ali Salanti, Michal Fried, Thor G. Theander, Benoit Gamain, Patrick E. Duffy

Summary: This study investigated the functional antibody response and antibody boosting during PM episodes in Aotus monkeys immunized with placental malaria vaccine (PMV) candidates. The results showed that PMV candidates induced functional antibodies with limited heterologous activity in the monkeys, similar to human responses. The Aotus model appears to be suitable for preclinical downselection of PMV candidates and assessment of antibody boosting.

LAB ANIMAL (2023)

Article Biochemistry & Molecular Biology

Endothelial protein C receptor binding induces conformational changes to severe malaria-associated group A PfEMP1

Sai Sundar Rajan Raghavan, Louise Turner, Rasmus W. Jensen, Nicolai Tidemand Johansen, Daniel Skjold Jensen, Pontus Gourdon, Jinqiu Zhang, Yong Wang, Thor Grundtvig Theander, Kaituo Wang, Thomas Lavstsen

Summary: Using Cryo-EM and PfEMP1 sequence diversity analysis, it was found that the CIDRa1 domains of group A PfEMP1 interact with the adjacent DBLa1 domain through central, conserved residues of the EPCR-binding site to form a compact conformation. Upon EPCR binding, the DBLa1 domain is displaced, and the EPCR-binding helix of CIDRa1 undergoes a rearrangement to reach a stable EPCR-bound conformation. This may represent a conformational masking mechanism for immune evasion in the PfEMP1 family.

STRUCTURE (2023)

Article Multidisciplinary Sciences

Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines

Julie Van Coillie, Tamas Pongracz, Tonci Sustic, Wenjun Wang, Jan Nouta, Mathieu Le Gars, Sofie Keijzer, Federica Linty, Olvi Cristianawati, Jim B. D. Keijser, Remco Visser, Lonneke A. van Vught, Marleen A. Slim, Niels van Mourik, Merel J. Smit, Adam Sander, David E. Schmidt, Maurice Steenhuis, Theo Rispens, Morten A. Nielsen, Benjamin G. Mordmueller, Alexander P. J. Vlaar, C. Ellen van der Schoot, Ramon Roozendaal, Manfred Wuhrer, Gestur Vidarsson

Summary: In this study, the glycosylation profiles of anti-S IgG1 Fc in response to mRNA, adenoviral, and protein-based COVID-19 vaccines were compared using mass spectrometry (MS). The results showed variations in the glycosylation patterns between different vaccine platforms and individuals, but overall, vaccine-induced anti-S IgG glycosylation was dynamic with marked overlaps.

ISCIENCE (2023)

No Data Available